Loading...
•
Sep 28, 2024
Bioventus Q3 2024 Earnings Report
Reported strong financial results with double-digit organic growth and increased cash flow.
Key Takeaways
Bioventus reported a 15.0% increase in worldwide revenue to $139.0 million, driven by double-digit growth in Pain Treatments and Surgical Solutions. The company's net loss from continuing operations was $5.4 million, with adjusted EBITDA advancing 8.4% to $23.6 million.
Q3 revenue advanced by 15.0%, marking the fourth consecutive quarter of double-digit organic growth.
Q3 gross margin expanded by 200 bps.
Q3 cash from operations reached $10.3 million, an increase of $18.6 million compared to the previous year.
Reached an agreement to divest the Company's Advanced Rehabilitation Business for up to $45.0 million.
Forward Guidance
For the twelve months ending December 31, 2024, the Company now expects net sales of $562 million to $567 million, Adjusted EBITDA of $104 million to $107 million and Non-GAAP EPS of $0.40 to $0.42.
Positive Outlook
- Net sales of $562 million to $567 million, reflecting an increase of $2.5 million from the midpoint of previous guidance
- Adjusted EBITDA of $104 million to $107 million
- Non-GAAP EPS of $0.40 to $0.42, reflecting an increase of $0.02 from the midpoint of previous guidance
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...